Oncolytics Biotech Inc.
ONCY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.92 | 0.42 | -1.72 |
| FCF Yield | -27.07% | -24.08% | -18.28% | -24.16% |
| EV / EBITDA | -2.45 | -2.48 | -4.35 | -2.08 |
| Quality | ||||
| ROIC | -254.96% | -97.68% | -85.30% | -60.45% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.85 | 1.03 | 0.94 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 4.40% | -21.55% | -3.04% | -2.82% |
| Safety | ||||
| Net Debt / EBITDA | 0.43 | 1.02 | 0.42 | 1.58 |
| Interest Coverage | 0.00 | 0.00 | -54.11 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -979.98 | -2,096.89 | -479.60 |